$12.9 Million Transaction Includes Approximately $3.4 Million of New Fundingand a $9.5 Million Full Cancellation of Outstanding Senior Notesand Extinguishment of Series B Preferred Shares
Continued here:
Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024.
Read more:
T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Read more:
TELA Bio to Announce Second Quarter 2024 Financial Results
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
Read more from the original source:
Sanofi: Information concerning the total number of voting rights and shares – June 2024
BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) in a best efforts public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.
Continued here:
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announces that at its Annual Meeting of Shareholders (the “Meeting”) reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company’s independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration.
Read more here:
Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders
SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance.
Read the rest here:
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
All dollar amounts reflected in Canadian dollars unless otherwise stated.
View original post here:
Rakovina Therapeutics Provides Update on Previously Announced Private Placement
BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $0.30 per share, for expected gross proceeds of $3,000,000, before deducting placement agent commissions and offering expenses. All of the shares of common stock are being offered by the Company. The offering is expected to close on July 24, 2024, subject to satisfaction of customary closing conditions.
See more here:
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
A seventh person has essentially been cured of HIV after receiving a stem cell transplant nearly a decade ago, doctors announced Thursday.
The 60-year-old unidentified German man was suffering from acute myeloid leukemia when he underwent the risky procedure to replace his unhealthy bone marrow in October 2015.
He quit taking anti-retroviral drugs which stop HIV from reproducing in September 2018. He remains in viral remission and appears to be cancer-free.
A healthy person has many wishes, a sick person only one, the man, who wishes to remain anonymous, said of his progress.
Dr. Christian Gaebler, a physician-scientist at the Charit-Universittsmedizin Berlin, is slated to present the case next week at the 25thInternational AIDS Conference.
The longer we see these HIV remissions without any HIV therapy, the more confidence we can get that were probably seeing a case where we really have eradicated all competent HIV, Gaebler said.
At a news conference last week, International AIDS Society President Sharon Lewin cautioned against using the word cure.
Still, she said, being in remission for more than five years means he would be close to being considered cured.
There is one major difference between the German mans case and most of the rest.
Five of the other six patients received stem cells from donors with two copies of a rare genetic mutation that stops HIV from replicating.
The German patient is said to be the first to have received stem cells from a donor with just one copy of the mutated gene and he had a copy of the gene himself.
About1% of Caucasians have two copies of thedefective gene, while 10% to 18% of people with European heritage are estimated to have one copy of the gene, thus expanding the potential donor pool.
Some 39 million people around the world are living with HIV, the virus that causes AIDS. Very few will be able to access this treatment, as it is reserved for those with HIV and aggressive leukemia.
Subscribe to our weekly Post Care newsletter!
The rest is here:
7th person likely cured of HIV in a remarkable case - New York Post